Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

LumiraDx Ltd (LMDXF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.020 -0.005    -21.00%
06/05 - Closed. Currency in USD ( Disclaimer )
After Hours
0.019
-0.001
-5.000%
20:55:21 - Delayed Data
  • Volume: 467,912
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.018 - 0.025
Type:  Equity
Market:  United States
LumiraDx 0.020 -0.005 -21.00%

LumiraDx Company Profile

 
Read the LumiraDx Ltd company profile to learn more about the business and the management team. View LumiraDx Ltd facts about employee data, company products and services, and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

1210

Equity Type

ORD

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Contact Information

Address 3 More London Riverside
London, SE1 2AQ
United Kingdom
Phone 44 11 7284 2535
Fax -

Top Executives

Name Age Since Title
Bruce Edward Keogh 68 2018 Independent Non-Employee Director
Donald M. Berwick 76 2018 Independent Non-Employee Director
Troyen A. Brennan 68 2016 Non-Employee Director
George R. Neble 66 2020 Independent Co-Chairman of the Board
Lurene Julia Wong Joseph 63 2016 Independent Co-Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LMDXF Price Commentary

Write your thoughts about LumiraDx Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Albert Gb
Albert Gb Jan 04, 2024 16:42
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The Lumiradx Ltd share price will soon rise by 50% in January 2024 due to a number of factors, including: • FDA approval of its lung cancer diagnostic device, the LumiraDx Lung Cancer Assay. This device is a blood test that can detect lung cancer in its early stages, when it is most treatable. The FDA approval was a major milestone for the company and generated great enthusiasm among investors. • Expectations that the company will obtain more FDA approvals in the future. Lumiradx is developing a number of other diagnostic devices, including blood tests for breast cancer, ovarian cancer and Alzheimer's disease. Investors expect the company to obtain more FDA approvals in the coming years, which could lead to significant revenue growth. • The general increase in interest in medical technology companies. Investors are increasingly interested in companies that develop new technologies to diagnose and treat diseases. Lumiradx is one of the leading companies in the medical technology field, making it an attractive investment for investors. Notably, the rise in Lumiradx's stock price came after the company announced that its lung cancer diagnostic device, the LumiraDx Lung Cancer Assay, had received FDA approval. This approval will be an important milestone for the company, as it allows it to commercialize its device. The device is a blood test that can detect lung cancer in its early stages, when it is most treatable. The FDA approval of Lumiradx is an example of how medical technology companies can generate significant investor interest. Investors are increasingly interested in companies that develop new technologies to diagnose and treat diseases. Lumiradx is one of the leading companies in the medical technology field, making it an attractive investment for investors.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email